;PMID: 11520139
;source_file_707.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:40..193] = [t:40..193]
;2)section:[e:197..283] = [t:197..283]
;3)section:[e:287..405] = [t:287..405]
;4)sentence:[e:409..419] = [t:409..419]
;5)sentence:[e:420..609] = [t:420..609]
;6)sentence:[e:610..750] = [t:610..750]
;7)sentence:[e:751..927] = [t:751..927]
;8)sentence:[e:928..936] = [t:928..936]
;9)sentence:[e:938..1103] = [t:938..1103]
;10)sentence:[e:1104..1112] = [t:1104..1112]
;11)sentence:[e:1113..1250] = [t:1113..1250]
;12)sentence:[e:1251..1394] = [t:1251..1394]
;13)sentence:[e:1395..1507] = [t:1395..1507]
;14)sentence:[e:1508..1582] = [t:1508..1582]
;15)sentence:[e:1583..1788] = [t:1583..1788]
;16)sentence:[e:1789..1800] = [t:1789..1800]
;17)sentence:[e:1801..2006] = [t:1801..2006]
;18)section:[e:2007..2037] = [t:2007..2037]
;19)section:[e:2041..2086] = [t:2041..2086]

;section 0 Span:0..35
;Gynecol Oncol  2001 Sep;82(3):450-5
(SEC
  (FRAG (NNP:[0..7] Gynecol) (NNP:[8..13] Oncol) (CD:[15..19] 2001)
        (CC:[20..27] Sep;82-LRB-) (CD:[27..28] 3) (-RRB-:[28..29] -RRB-)
        (CD:[29..33] :450) (::[33..34] -) (CD:[34..35] 5)))

;sentence 1 Span:40..193
;Cytoplasmic/nuclear expression without mutation of exon 3 of the beta-catenin
; gene is frequent in the development of the neoplasm of the uterine cervix.
;[79..87]:variation-event:"mutation"
;[91..97]:variation-location:"exon 3"
;[105..117]:gene-rna:"beta-catenin"
;[162..192]:malignancy:"neoplasm of the uterine cervix"
(SENT
  (S-HLN
    (NP-SBJ
      (NP
        (NP (JJ:[40..51] Cytoplasmic)
          (NML-1 (-NONE-:[51..51] *P*)))
        (SYM:[51..52] /)
        (NP (JJ:[52..59] nuclear)
          (NML-1 (NN:[60..70] expression))))
      (PP (IN:[71..78] without)
        (NP
          (NP (NN:[79..87] mutation))
          (PP (IN:[88..90] of)
            (NP
              (NP (NN:[91..95] exon) (CD:[96..97] 3))
              (PP (IN:[98..100] of)
                (NP (DT:[101..104] the) (NN:[105..117] beta-catenin)
                    (NN:[119..123] gene))))))))
    (VP (VBZ:[124..126] is)
      (ADJP-PRD (JJ:[127..135] frequent)
        (PP (IN:[136..138] in)
          (NP
            (NP (DT:[139..142] the) (NN:[143..154] development))
            (PP (IN:[155..157] of)
              (NP
                (NP (DT:[158..161] the) (NN:[162..170] neoplasm))
                (PP (IN:[171..173] of)
                  (NP (DT:[174..177] the) (JJ:[178..185] uterine)
                      (NN:[186..192] cervix)))))))))
    (.:[192..193] .)))

;section 2 Span:197..283
;Shinohara A, Yokoyama Y, Wan X, Takahashi Y, Mori Y, Takami T, Shimokawa K, 
;Tamaya T.
(SEC
  (FRAG (NNP:[197..206] Shinohara) (NNP:[207..208] A) (,:[208..209] ,)
        (NNP:[210..218] Yokoyama) (NNP:[219..220] Y) (,:[220..221] ,)
        (NNP:[222..225] Wan) (NNP:[226..227] X) (,:[227..228] ,)
        (NNP:[229..238] Takahashi) (NNP:[239..240] Y) (,:[240..241] ,)
        (NNP:[242..246] Mori) (NNP:[247..248] Y) (,:[248..249] ,)
        (NNP:[250..256] Takami) (NNP:[257..258] T) (,:[258..259] ,)
        (NNP:[260..269] Shimokawa) (NNP:[270..271] K) (,:[271..272] ,)
        (NNP:[274..280] Tamaya) (NNP:[281..283] T.)))

;section 3 Span:287..405
;Department of Obstetrics and Gynecology, Gifu University School of Medicine,
;40  Tsukasa-machi, Gifu, 500-8705, Japan.
(SEC
  (FRAG (NNP:[287..297] Department) (IN:[298..300] of)
        (NNP:[301..311] Obstetrics) (CC:[312..315] and)
        (NNP:[316..326] Gynecology) (,:[326..327] ,) (NNP:[328..332] Gifu)
        (NNP:[333..343] University) (NNP:[344..350] School) (IN:[351..353] of)
        (NNP:[354..362] Medicine) (,:[362..363] ,) (CD:[364..366] 40)
        (NNP:[368..375] Tsukasa) (::[375..376] -) (NN:[376..381] machi)
        (,:[381..382] ,) (NNP:[383..387] Gifu) (,:[387..388] ,)
        (CD:[389..392] 500) (::[392..393] -) (CD:[393..397] 8705)
        (,:[397..398] ,) (NNP:[399..404] Japan) (.:[404..405] .)))

;sentence 4 Span:409..419
;OBJECTIVE:
(SENT
  (NP (NN:[409..418] OBJECTIVE) (::[418..419] :)))

;sentence 5 Span:420..609
;The dual function of beta-catenin (e.g., as an intermediate protein  between
;adherence junctions and the microfilaments, and as a mediator of the Wnt 
;signaling pathway) is currently known.
;[441..453]:gene-protein:"beta-catenin"
;[566..569]:gene-protein:"Wnt"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[420..423] The) (JJ:[424..428] dual) (NN:[429..437] function))
      (PP (IN:[438..440] of)
        (NP (NN:[441..453] beta-catenin)))
      (PRN (-LRB-:[454..455] -LRB-)
        (PP (FW:[455..459] e.g.) (,:[459..460] ,)
          (PP
            (PP (IN:[461..463] as)
              (NP
                (NP (DT:[464..466] an) (JJ:[467..479] intermediate)
                    (NN:[480..487] protein))
                (PP (IN:[489..496] between)
                  (NP
                    (NP (NN:[497..506] adherence) (NNS:[507..516] junctions))
                    (CC:[517..520] and)
                    (NP (DT:[521..524] the) (NNS:[525..539] microfilaments))))))
            (,:[539..540] ,) (CC:[541..544] and)
            (PP (IN:[545..547] as)
              (NP
                (NP (DT:[548..549] a) (NN:[550..558] mediator))
                (PP (IN:[559..561] of)
                  (NP (DT:[562..565] the) (NN:[566..569] Wnt)
                      (NN:[571..580] signaling) (NN:[581..588] pathway)))))))
        (-RRB-:[588..589] -RRB-)))
    (VP (VBZ:[590..592] is)
      (ADVP-TMP (RB:[593..602] currently))
      (VP (VBN:[603..608] known)
        (NP-1 (-NONE-:[608..608] *))))
    (.:[608..609] .)))

;sentence 6 Span:610..750
;Stabilization of beta-catenin and  subsequent activation of the Wnt signaling
;pathway are involved in the  development of some malignancies.
;[627..639]:gene-protein:"beta-catenin"
;[674..677]:gene-protein:"Wnt"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (NN:[610..623] Stabilization))
        (PP (IN:[624..626] of)
          (NP (NN:[627..639] beta-catenin))))
      (CC:[640..643] and)
      (NP
        (NP (JJ:[645..655] subsequent) (NN:[656..666] activation))
        (PP (IN:[667..669] of)
          (NP (DT:[670..673] the) (NN:[674..677] Wnt) (NN:[678..687] signaling)
              (NN:[688..695] pathway)))))
    (VP (VBP:[696..699] are)
      (VP (VBN:[700..708] involved)
        (NP-1 (-NONE-:[708..708] *))
        (PP-CLR (IN:[709..711] in)
          (NP
            (NP (DT:[712..715] the) (NN:[717..728] development))
            (PP (IN:[729..731] of)
              (NP (DT:[732..736] some) (NNS:[737..749] malignancies)))))))
    (.:[749..750] .)))

;sentence 7 Span:751..927
;We analyzed the immunohistochemical  localization of beta-catenin and the
;somatic mutation of exon 3 of the  beta-catenin gene in the malignant
;phenotype of the uterine cervix.
;[804..816]:gene-protein:"beta-catenin"
;[833..841]:variation-event:"mutation"
;[845..851]:variation-location:"exon 3"
;[860..872]:gene-rna:"beta-catenin"
;[885..926]:malignancy:"malignant phenotype of the uterine cervix"
(SENT
  (S
    (NP-SBJ (PRP:[751..753] We))
    (VP (VBD:[754..762] analyzed)
      (NP
        (NP
          (NP (DT:[763..766] the) (JJ:[767..786] immunohistochemical)
              (NN:[788..800] localization))
          (PP (IN:[801..803] of)
            (NP (NN:[804..816] beta-catenin))))
        (CC:[817..820] and)
        (NP
          (NP (DT:[821..824] the) (JJ:[825..832] somatic)
              (NN:[833..841] mutation))
          (PP (IN:[842..844] of)
            (NP
              (NP (NN:[845..849] exon) (CD:[850..851] 3))
              (PP (IN:[852..854] of)
                (NP (DT:[855..858] the) (NN:[860..872] beta-catenin)
                    (NN:[873..877] gene)))))))
      (PP (IN:[878..880] in)
        (NP
          (NP (DT:[881..884] the) (JJ:[885..894] malignant)
              (NN:[895..904] phenotype))
          (PP (IN:[905..907] of)
            (NP (DT:[908..911] the) (JJ:[912..919] uterine)
                (NN:[920..926] cervix))))))
    (.:[926..927] .)))

;sentence 8 Span:928..936
;METHODS:
(SENT
  (NP (NNS:[928..935] METHODS) (::[935..936] :)))

;sentence 9 Span:938..1103
;Immunohistochemical localization of beta-catenin and mutation of exon 3 of
;the  beta-catenin gene were analyzed in 38 precancerous lesions and 43
;cancerous  lesions.
;[974..986]:gene-protein:"beta-catenin"
;[991..999]:variation-event:"mutation"
;[1003..1009]:variation-location:"exon 3"
;[1018..1030]:gene-rna:"beta-catenin"
;[1056..1076]:malignancy:"precancerous lesions"
;[1084..1102]:malignancy:"cancerous  lesions"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (JJ:[938..957] Immunohistochemical) (NN:[958..970] localization))
        (PP (IN:[971..973] of)
          (NP (NN:[974..986] beta-catenin))))
      (CC:[987..990] and)
      (NP
        (NP (NN:[991..999] mutation))
        (PP (IN:[1000..1002] of)
          (NP
            (NP (NN:[1003..1007] exon) (CD:[1008..1009] 3))
            (PP (IN:[1010..1012] of)
              (NP (DT:[1013..1016] the) (NN:[1018..1030] beta-catenin)
                  (NN:[1031..1035] gene)))))))
    (VP (VBD:[1036..1040] were)
      (VP (VBN:[1041..1049] analyzed)
        (NP-1 (-NONE-:[1049..1049] *))
        (PP-LOC (IN:[1050..1052] in)
          (NP
            (NP (CD:[1053..1055] 38)
               (JJ:[1056..1068] precancerous) (NNS:[1069..1076] lesions))
            (CC:[1077..1080] and)
            (NP (CD:[1081..1083] 43)
               (JJ:[1084..1093] cancerous) (NNS:[1095..1102] lesions))))))
    (.:[1102..1103] .)))

;sentence 10 Span:1104..1112
;RESULTS:
(SENT
  (NP (NNS:[1104..1111] RESULTS) (::[1111..1112] :)))

;sentence 11 Span:1113..1250
;In normal cervix, beta-catenin was observed around the plasma  membrane of
;the cells in the basal and parabasal layers of the epithelium.
;[1131..1143]:gene-protein:"beta-catenin"
(SENT
  (S
    (PP-LOC (IN:[1113..1115] In)
      (NP (JJ:[1116..1122] normal) (NN:[1123..1129] cervix)))
    (,:[1129..1130] ,)
    (NP-SBJ-2 (NN:[1131..1143] beta-catenin))
    (VP (VBD:[1144..1147] was)
      (VP (VBN:[1148..1156] observed)
        (NP-2 (-NONE-:[1156..1156] *))
        (PP-LOC (IN:[1157..1163] around)
          (NP
            (NP (DT:[1164..1167] the) (NN:[1168..1174] plasma)
                (NN:[1176..1184] membrane))
            (PP (IN:[1185..1187] of)
              (NP
                (NP (DT:[1188..1191] the) (NNS:[1192..1197] cells))
                (PP-LOC (IN:[1198..1200] in)
                  (NP
                    (NP (DT:[1201..1204] the)
                      (NML
                        (NML (JJ:[1205..1210] basal)
                          (NML-1 (-NONE-:[1210..1210] *P*)))
                        (CC:[1211..1214] and)
                        (NML (JJ:[1215..1224] parabasal)
                          (NML-1 (NNS:[1225..1231] layers)))))
                    (PP (IN:[1232..1234] of)
                      (NP (DT:[1235..1238] the) (NN:[1239..1249] epithelium)))))))))))
    (.:[1249..1250] .)))

;sentence 12 Span:1251..1394
;The  frequency of cytoplasmic/nuclear beta-catenin expression correlated with
;a high  histological grade of cervical intraepithelial neoplasia.
;[1289..1301]:gene-protein:"beta-catenin"
;[1331..1393]:malignancy:"high  histological grade of cervical intraepithelial
;neoplasia"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[1251..1254] The) (NN:[1256..1265] frequency))
      (PP (IN:[1266..1268] of)
        (NP
          (NP (JJ:[1269..1280] cytoplasmic)
            (NML-2 (-NONE-:[1280..1280] *P*)))
          (SYM:[1280..1281] /)
          (NP (JJ:[1281..1288] nuclear)
            (NML-2 (NN:[1289..1301] beta-catenin) (NN:[1302..1312] expression))))))
    (VP (VBD:[1313..1323] correlated)
      (PP-CLR (IN:[1324..1328] with)
        (NP
          (NP (DT:[1329..1330] a) (JJ:[1331..1335] high)
              (JJ:[1337..1349] histological) (NN:[1350..1355] grade))
          (PP (IN:[1356..1358] of)
            (NP (JJ:[1359..1367] cervical) (JJ:[1368..1383] intraepithelial)
                (NN:[1384..1393] neoplasia))))))
    (.:[1393..1394] .)))

;sentence 13 Span:1395..1507
;Among invasive  carcinomas, 11 (73%) of 15 samples showed cytoplasmic/nuclear
;localization to  variable extents.
;[1401..1421]:malignancy:"invasive  carcinomas"
(SENT
  (S
    (PP (IN:[1395..1400] Among)
      (NP (JJ:[1401..1409] invasive) (NNS:[1411..1421] carcinomas)))
    (,:[1421..1422] ,)
    (NP-SBJ
      (NP (CD:[1423..1425] 11)
        (PRN (-LRB-:[1426..1427] -LRB-)
          (NP (CD:[1427..1429] 73) (NN:[1429..1430] %))
          (-RRB-:[1430..1431] -RRB-)))
      (PP (IN:[1432..1434] of)
        (NP (CD:[1435..1437] 15) (NNS:[1438..1445] samples))))
    (VP (VBD:[1446..1452] showed)
      (NP
        (NP
          (NP (JJ:[1453..1464] cytoplasmic)
            (NML-1 (-NONE-:[1464..1464] *P*)))
          (SYM:[1464..1465] /)
          (NP (JJ:[1465..1472] nuclear)
            (NML-1 (NN:[1473..1485] localization))))
        (PP (TO:[1486..1488] to)
          (NP (JJ:[1490..1498] variable) (NNS:[1499..1506] extents)))))
    (.:[1506..1507] .)))

;sentence 14 Span:1508..1582
;A mutational analysis showed that mutation occurred in 7 of 68  specimens.
;[1542..1550]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ (DT:[1508..1509] A) (JJ:[1510..1520] mutational)
            (NN:[1521..1529] analysis))
    (VP (VBD:[1530..1536] showed)
      (SBAR (IN:[1537..1541] that)
        (S
          (NP-SBJ (NN:[1542..1550] mutation))
          (VP (VBD:[1551..1559] occurred)
            (PP (IN:[1560..1562] in)
              (NP
                (NP (CD:[1563..1564] 7))
                (PP (IN:[1565..1567] of)
                  (NP (CD:[1568..1570] 68) (NNS:[1572..1581] specimens)))))))))
    (.:[1581..1582] .)))

;sentence 15 Span:1583..1788
;Six cases with mutations revealed cytoplasmic/nuclear beta-catenin 
;expression, though 32 (84%) of the 38 samples showing cytoplasmic/nuclear 
;beta-catenin expression were not associated with the mutation.
;[1598..1607]:variation-event:"mutations"
;[1637..1649]:gene-protein:"beta-catenin"
;[1726..1738]:gene-protein:"beta-catenin"
;[1779..1787]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1583..1586] Six) (NNS:[1587..1592] cases))
      (PP (IN:[1593..1597] with)
        (NP (NNS:[1598..1607] mutations))))
    (VP (VBD:[1608..1616] revealed)
      (NP
        (NML (JJ:[1617..1628] cytoplasmic)
          (NML-3 (-NONE-:[1628..1628] *P*)))
        (SYM:[1628..1629] /)
        (NML (JJ:[1629..1636] nuclear)
          (NML-3 (NN:[1637..1649] beta-catenin) (NN:[1651..1661] expression))))
      (,:[1661..1662] ,)
      (SBAR-ADV (IN:[1663..1669] though)
        (S
          (NP-SBJ-2
            (NP (CD:[1670..1672] 32)
              (PRN (-LRB-:[1673..1674] -LRB-)
                (NP (CD:[1674..1676] 84) (NN:[1676..1677] %))
                (-RRB-:[1677..1678] -RRB-)))
            (PP (IN:[1679..1681] of)
              (NP
                (NP (DT:[1682..1685] the) (CD:[1686..1688] 38)
                    (NNS:[1689..1696] samples))
                (VP (VBG:[1697..1704] showing)
                  (NP
                    (NML (JJ:[1705..1716] cytoplasmic)
                      (NML-1 (-NONE-:[1716..1716] *P*)))
                    (SYM:[1716..1717] /)
                    (NML (JJ:[1717..1724] nuclear)
                      (NML-1 (NN:[1726..1738] beta-catenin)
                             (NN:[1739..1749] expression))))))))
          (VP (VBD:[1750..1754] were) (RB:[1755..1758] not)
            (VP (VBN:[1759..1769] associated)
              (NP-2 (-NONE-:[1769..1769] *))
              (PP-CLR (IN:[1770..1774] with)
                (NP (DT:[1775..1778] the) (NN:[1779..1787] mutation))))))))
    (.:[1787..1788] .)))

;sentence 16 Span:1789..1800
;CONCLUSION:
(SENT
  (NP (NN:[1789..1799] CONCLUSION) (::[1799..1800] :)))

;sentence 17 Span:1801..2006
;These  results indicate that cytoplasmic/nuclear expression of beta-catenin
;is  associated with the malignant phenotype of the cervix, but the
;contribution of  mutation of the beta-catenin gene is limited.
;[1864..1876]:gene-protein:"beta-catenin"
;[1901..1934]:malignancy:"malignant phenotype of the cervix"
;[1961..1969]:variation-event:"mutation"
;[1977..1989]:gene-rna:"beta-catenin"
(SENT
  (S
    (NP-SBJ (DT:[1801..1806] These) (NNS:[1808..1815] results))
    (VP (VBP:[1816..1824] indicate)
      (SBAR (IN:[1825..1829] that)
        (S
          (S
            (NP-SBJ-3
              (NP
                (NP (JJ:[1830..1841] cytoplasmic)
                  (NML-2 (-NONE-:[1841..1841] *P*)))
                (SYM:[1841..1842] /)
                (NP (JJ:[1842..1849] nuclear)
                  (NML-2 (NN:[1850..1860] expression))))
              (PP (IN:[1861..1863] of)
                (NP (NN:[1864..1876] beta-catenin))))
            (VP (VBZ:[1877..1879] is)
              (VP (VBN:[1881..1891] associated)
                (NP-3 (-NONE-:[1891..1891] *))
                (PP-CLR (IN:[1892..1896] with)
                  (NP
                    (NP (DT:[1897..1900] the) (JJ:[1901..1910] malignant)
                        (NN:[1911..1920] phenotype))
                    (PP (IN:[1921..1923] of)
                      (NP (DT:[1924..1927] the) (NN:[1928..1934] cervix))))))))
          (,:[1934..1935] ,) (CC:[1936..1939] but)
          (S
            (NP-SBJ-1
              (NP (DT:[1940..1943] the) (NN:[1944..1956] contribution))
              (PP (IN:[1957..1959] of)
                (NP
                  (NP (NN:[1961..1969] mutation))
                  (PP (IN:[1970..1972] of)
                    (NP (DT:[1973..1976] the) (NN:[1977..1989] beta-catenin)
                        (NN:[1990..1994] gene))))))
            (VP (VBZ:[1995..1997] is)
              (VP (VBN:[1998..2005] limited)
                (NP-1 (-NONE-:[2005..2005] *))))))))
    (.:[2005..2006] .)))

;section 18 Span:2007..2037
;Copyright 2001 Academic Press.
(SEC
  (FRAG (NN:[2007..2016] Copyright) (CD:[2017..2021] 2001)
        (NNP:[2022..2030] Academic) (NNP:[2031..2036] Press) (.:[2036..2037] .)))

;section 19 Span:2041..2086
;PMID: 11520139 [PubMed - indexed for MEDLINE]
(SEC (NNP:[2041..2045] PMID) (::[2045..2046] :) (CD:[2047..2055] 11520139)
     (NN:[2056..2057] -LSB-) (NNP:[2057..2063] PubMed) (::[2064..2065] -)
     (NN:[2066..2073] indexed) (IN:[2074..2077] for)
     (NNP:[2078..2086] MEDLINE-RSB-))
